HROW

Harrow, Inc.

Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, TN. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx [sic], an ophthalmic-focused pharmaceutical company.

Harrow, Inc. (HROW) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Value (C). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C
Factor Score 2.2 / 5.0
Growth
B
Factor Score 3.4 / 5.0
Profitability
B+
Factor Score 3.6 / 5.0
Momentum
C
Factor Score 2.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 11.4
EV / EBITDA 84.2
Rev Growth YoY 38.6%
Gross Margin 73.5%
Price Return 3M -24.4%
Price Return 12M -14.0%
Catalyst Signal 0.00
Market Cap $1.1B
TTM Revenue $303.3M
Price / Sales 3.6
ROE -75.5%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C (2.2) B (3.4) B+ (3.6) C (2.3) C+ (2.6) C+ (2.8)
2026-11-05 C (2.2) B- (3.0) B+ (3.6) C- (1.9) C+ (2.7) C+ (2.7)
2026-10-29 C (2.2) B- (2.9) B+ (3.6) C- (1.9) C+ (2.7) C+ (2.7)
2026-10-22 C (2.3) B- (2.9) B+ (3.6) D+ (1.8) C+ (2.6) C+ (2.6)
2026-10-15 C (2.2) B- (2.9) B+ (3.6) D+ (1.8) C+ (2.6) C+ (2.6)
Page 1 of 3